BCR/ABL activates mdm2 mRNA translation via the La antigen

Cancer Cell

Volumn 3, Issue 2, 2003, Pages 145-160

  Trotta, Rossana ^a   Vignudelli, Tatiana ^b   Candini, Olivia ^b   Intine, Robert V ^c   Pecorari, Luisa ^b   Guerzoni, Clara ^a   Santilli, Giorgia ^a   Byrom, Mike W ^d   Goldoni, Silvia ^b   Ford, Lance P ^d   Caligiuri, Michael A ^e,f   Maraia, Richard J ^c   Perrotti, Danilo ^a   Calabretta, Bruno ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^d APPLIED BIOSYSTEMS   (United States)

^e OHIO STATE UNIVERSITY   (United States)

^f Cancer and Leukemia Group B Central Office   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; BCR ABL PROTEIN; GROWTH FACTOR; MESSENGER RNA; MUTANT PROTEIN; PROTEIN MDM2; PROTEIN P53; PROTEIN TYROSINE KINASE; ANTINEOPLASTIC AGENT; AUTOANTIGEN; GRB2 PROTEIN, HUMAN; GRB2 PROTEIN, MOUSE; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; GROWTH PROMOTOR; MDM2 PROTEIN, HUMAN; MDM2 PROTEIN, MOUSE; NUCLEAR PROTEIN; ONCOPROTEIN; PROTEIN; RIBONUCLEOPROTEIN; RNA BINDING PROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SMALL INTERFERING RNA; SS B ANTIGEN; SS-B ANTIGEN; TRANSCRIPTION FACTOR;

5' UNTRANSLATED REGION; ANIMAL CELL; APOPTOSIS; ARTICLE; BONE MARROW CELL; CELL LINE; CELL TRANSFORMATION; CHRONIC MYELOID LEUKEMIA; CORRELATION ANALYSIS; DOWN REGULATION; GENE OVEREXPRESSION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SAMPLING; STEM CELL; UPREGULATION; ANIMAL; DRUG EFFECT; DRUG RESISTANCE; GENETICS; HUMAN; METABOLISM; NORTHERN BLOTTING; PHYSIOLOGY; PROTEIN SYNTHESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALIA;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; AUTOANTIGENS; BLOTTING, NORTHERN; BLOTTING, WESTERN; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; GRB2 ADAPTOR PROTEIN; GROWTH SUBSTANCES; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MICE; NUCLEAR PROTEINS; PROTEIN BIOSYNTHESIS; PROTEIN-TYROSINE KINASES; PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBONUCLEOPROTEINS; RNA, MESSENGER; RNA, SMALL INTERFERING; RNA-BINDING PROTEINS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 0012956142     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(03)00020-5     Document Type: Article

References (69)

1. Barak Y., Gottlieb E., Juven-Gershon T., Oren M. Regulation of mdm2 expression by p53. alternative promoters produce transcripts with non identical translation potential Genes Dev. 8:1994;1739-1749.
2. Bi S., Lanza F., Goldman J.M. The involvement of "tumor suppressor" p53 in normal and chronic myelogenous leukemia hematopoiesis. Cancer Res. 54:1994;582-586.
3. Blandino G., Scardigli R., Rizzo M.G., Crescenzi M., Soddu S., Sacchi A. Wild-type p53 modulates apoptosis of normal, IL-3 deprived, hematopoietic cells. Oncogene. 10:1995;731-737.
4. Boyd S.D., Tsai K.Y., Jacks T. An intact HDM2 RING-finger domain is required for nuclear exclusion of p53. Nat. Cell Biol. 2:2000;563-568.
5. Broekhuis C.H., Neubauer G., van der Heijden A., Mann M., Proud C.G., van Venrooij W.J., Pruijn G.J. Detailed analysis of the phosphorylation of the human La (ss-B) auto-antigen. (De) phosphorylation does not affect its subcellular distribution. Biochemistry. 39:2000;3023-3033.
6. Brown C.Y., Mize G.J., Pineda M., George D.L., Morris D.R. Role of two upstream open reading frames in the translational control of oncogene mdm2. Oncogene. 18:1999;5631-5637.
7. Capoulade C., Bressac-de Paillerets B., Lefrere I., Ronsin M., Feunteun J., Tursz T., Wiels J. Overexpression of MDM2, due to enhanced translation, results in inactivation of wild-type p53 in Burkitt's lymphoma cells. Oncogene. 16:1998;1603-1610.
8. Cortez D., Kadlec L., Pendergast A.M. Structural and signaling requirements for BCR/ABL-mediated transformation and inhibition of apoptosis. Mol. Cell. Biol. 15:1995;5531-5541.
9. Craig A.W., Svitkin Y.V., Lee H.S., Belsham G.J., Sonenberg N. The La autoantigen contains a dimerization domain that is essential for enhancing translation. Mol. Cell. Biol. 17:1997;163-169.
10. Dai Z., Quackenbush R.C., Courtney K.D., Grove M., Cortez D., Reuther G.W., Pendergast A.M. Oncogenic Abl and Src tyrosine kinases elicit the ubiquitin-dependent degradation of target proteins through a Ras-independent pathway. Genes Dev. 12:1998;1415-1424.
11. Druker B.J., Tamura S., Buchdunger E., Ohno S., Segal G.M., Fanning S., Zimmermann J., Lydon N.B. Effects of a selective inhibitor of the ABL tyrosine kinase on the growth of BCR/ABL positive cells. Nat. Med. 2:1996;561-566.
12. Druker B.J., Sawyers C.L., Kantarjian H., Resta D.J., Reese S.F., Ford J.M., Capdeville R., Talpaz M. Activity of a specific inhibitor of the BCR/ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344:2001;1038-1042.
13. Elmaagacli A.H., Beelen D.W., Opalka B., Seeber S., Schaefer U.W. The amount of BCR/ABL fusion transcripts detected by the real-time quantitative polymerase chain reaction method in patients with Philadelphia chromosome positive chronic myeloid leukemia correlates with the disease stage. Ann. Hematol. 79:2000;424-431.
14. Faderl S., Kantarjian H.M., Estey E., Manshouri T., Chan C.Y., Rahman-Elsaied A., Kornblau S.M., Cortes J., Thomas D.A., Pierce S., et al. The prognostic significance of p16(INK4a) / p14(ARF) locus deletion and MDM2 protein expression in adult acute myelogenous leukemia. Cancer. 89:2000;1976-1982.
15. Fan H., Goodier J.L., Chamberlain J.R., Engelke D.R., Maraia R.J. 5′ processing of tRNA precursors can be modulated by the human La antigen phosphoprotein. Mol. Cell. Biol. 18:1998;3201-3211.
16. Fang G., Kim C.N., Perkins C.L., Ramadevi N., Winston E., Wittmann S., Bhalla K.N. CGP571148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to anti-leukemic drugs. Blood. 96:2000;2246-2253. a.
17. Fang S., Jensen J.P., Ludwig R.L., Wousden K.H., Weissman A.M. Mdm2 is a RING- finger-dependent ubiquitin protein ligase for itself and p53. J. Biol. Chem. 275:2000;8945-8951. b.
18. Feinstein E., Cimino G., Gale R.P., Alimena G., Berthier R., Kishi K., Goldman J., Zaccaria A., Berrebi A., Canaani E. p53 in chronic myelogenous leukemia in acute phase. Proc. Natl. Acad. Sci. USA. 88:1991;6293-6297.
19. Freedman D.A., Levine A.J. Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. Mol. Cell. Biol. 18:1998;7288-7293.
20. Fu L., Minden M.D., Benchimol S. Translational Regulation of human p53 gene expression. EMBO J. 15:1996;4392-4401.
21. Gaiger A., Henn T., Horth E., Geissler K., Mitterbauer G., Maier-Dobersberger T., Greinix H., Mannhalter C., Haas O.A., Lechner K., et al. Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression. Blood. 86:1995;2371-2378.
22. Geyer R.K., Yu Z.K., Maki C.G. The MDM2 RING-finger domain is required to promote p53 nuclear export. Nat. Cell Biol. 2:2000;569-573.
23. Goetz A.W., van der Kuip H., Maya R., Oren M., Aulitzky W.E. Requirement for MDM2 in the survival effects of BCR/ABL and interleukin-3 in hematopoietic cells. Cancer Res. 61:2001;7635-7641.
24. Gordon M.Y. Biological consequences of the BCR/ABL fusion gene in humans and mice. J. Clin. Pathol. 52:1999;719-722.
25. Gotoh A., Miyazawa K., Ohyashiki K., Toyama K. Potential molecules implicated in downstream signaling pathways of p185 BCR/ABL in Ph+ ALL involve GTPase-activating protein, phospholipase C-gamma 1, and phosphatidylinositol 3′-kinase. Leukemia. 8:1994;115-120.
26. Habelhah H., Shah K., Huang L., Ostareck-Lederer A., Burlingame A.L., Shokat K.M., Hentze M.W., Ronai Z. ERK phosphorylation drives cytoplasmic accumulation of hnRNP-K and inhibition of mRNA translation. Nat. Cell Biol. 3:2001;325-330.
27. Haupt Y., Maya R., Kazaz A., Oren M. Mdm2 promotes the rapid degradation of p53. Nature. 387:1997;296-299.
28. Hendrick J.P., Wolin S.L., Rinke J., Lerner M.R., Steitz J.A. Ro small cytoplasmic ribonucleoproteins are a subclass of La ribonucleoproteins. further characterization of the Ro and La small ribonucleoproteins from uninfected mammalian cells Mol. Cell. Biol. 1:1981;1138-1149.
29. Holcik M., Korneluk R.G. Functional characterization of the X-linked inhibitor of apoptosis (XIAP) internal ribosome entry site element. role of La autoantigen in XIAP translation Mol. Cell. Biol. 20:2000;4648-4657.
30. (bcr/abl)-expressing hematopoietic cells. a transgenic study for blast crisis of human CML Blood. 95:2000;1144-1150.
31. Huettner C.S., Zhang P., Van Etten R.A., Tenen D.G. Reversibility of acute B-cell leukemia induced by BCR/ABL1. Nat. Genet. 24:2000;57-60.
32. Iervolino A., Santilli G., Trotta R., Guerzoni C., Cesi V., Bergamaschi A., Gambacorti-Passerini C., Calabretta B., Perrotti D. hnRNP A1 nucleocytoplasmic shuttling activity is required for normal myelopoiesis and BCR/ABL leukemogenesis. Mol. Cell. Biol. 22:2002;2255-2266.
33. Intine R.V., Dundr M., Misteli T., Maraia R.J. Aberrant Nuclear Trafficking of La Protein Leads to Disordered Processing of Associated Precursor tRNAs. Mol. Cell. 9:2002;1113-1123.
34. Intine R.V.A., Sakulich A.L., Kodurai S.B., Huang Y., Pierstorff E., Goodier J.L., Phan L., Maraia R.J. Control of transfer RNA maturation by phosphorylation of the human La antigen on serine 366. Mol. Cell. 6:2000;339-348.
35. Kantarjian H.M., Keating M.J., Talpaz M., Walters R.S., Smith T.L., Cork A., McCredie K.B., Freireich E.J. Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients. Am. J. Med. 83:1987;445-454.
36. Kantarjian H.M., Deisseroth A., Kuzzrock R., Estrov Z., Talpaz M. Chronic myelogenous leukemia. a concise update Blood. 82:1993;691-703.
37. Kastan M.B., Radin A.I., Kuerbitz S.J., Onyekwere O., Wolkow C.A., Civin C.I., Stone K.D., Woo T., Ravindranath Y., Craig R.W. Levels of p53 protein increase with maturation in human hematopoietic cells. Cancer Res. 51:1991;4279-4286.
38. Kim Y.K., Back S.H., Rho J., Lee S.H., Jang S.K. La autoantigen enhances translation of BiP mRNA. Nucleic Acids Res. 29:2001;5009-5016.
39. Kubbutat M.H., Jones S.N., Vousden K.H. Regulation of p53 stability by Mdm2. Nature. 387:1997;299-303.
40. Lakin N.D., Jackson S.P. Regulation of p53 in response to DNA damage. Oncogene. 18:1999;7644-7655.
41. Landers J.E., Haines D.S., Strauss J.F. 3rd, George D.L. Enhanced translation. a novel mechanism of mdm2 oncogene overexpression identified in human tumor cells Oncogene. 9:1994;2745-2750.
42. Le Good J.A., Ziegler W.H., Parekh D.B., Alessi D.R., Cohen P., Parker P.J. Protein kinase isotypes controlled by phosphoinositide 3-kinase through the protein kinase PDK1. Science. 281:1998;2042-2045.
43. Lubbert M., Miller C.W., Crawford L., Koeffler H.P. p53 in chronic myelogenous leukemia. Study of mechanisms of differential expression. J. Exp. Med. 167:1988;873-886.
44. Luscher B., Eisenman R.N. c-myc and c-myb protein degradation. effect of metabolic inhibitors and heat shock Mol. Cell. Biol. 8:1988;2504-2512.
45. Maraia R.J., Intine R.V. Recognition of nascent RNA by the human La antigen. conserved and divergent features of structure and function Mol. Cell. Biol. 21:2001;367-379.
46. Momand J., Zambetti G.P., Olson D.C., George D., Levine A.J. The mdm2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 69:1992;1237-1245.
47. Newton A.C. Protein kinase C. structure, function, and regulation J. Biol. Chem. 270:1995;28495-28498.
48. Olson D.C., Marechal V., Momand J., Chen J., Romocki C., Levine A.J. Identification and characterization of multiple mdm-2 proteins and mdm-2-p53 protein complexes. Oncogene. 8:1993;2353-2360.
49. Osarogiagbon U.R., McGlave P.B. Chronic myelogenous leukemia. Curr. Opin. Hematol. 6:1999;241-246.
50. bcr/abl-transduced bone marrow. Blood. 92:1998;3780-3792.
51. Perrotti D., Iervolino A., Cesi V., Cirinnà M., Lombardini S., Grassilli E., Bonatti S., Claudio P.P., Calabretta B. BCR/ABL prevents a jun-mediated and proteasome-dependent FUS(TLS) proteolysis through a protein kinase C βII-dependent pathway. Mol. Cell. Biol. 20:2000;6159-6169.
52. Perrotti D., Cesi V., Trotta R., Guerzoni C., Santilli G., Campbell K., Iervolino A., Condorelli F., Gambacorti-Passerini C., Caligiuri M.A., Calabretta B. BCR/ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2. Nat. Genet. 30:2002;48-58.
53. Pierce A., Spooncer E., Wooley S., Dive C., Francis J.M., Miyan J., Owen-Lynch P.J., Dexter T.M., Whetton A.D. BCR/ABL protein tyrosine kinase activity induces a loss of p53 that mediates a delay in myeloid differentiation. Oncogene. 19:2000;5487-5497.
54. Ries S., Biederer C., Woods D., Shifman O., Shirasawa S., Sasazuki T., McMahon M., Oren M., McCormick F. Opposing effects of RAS on p53. transcriptional activation of mdm2 and induction of p19ARF Cell. 103:2000;321-330.
55. Sawyers C.L. Chronic myeloid leukemia. N. Engl. J. Med. 340:1999;1330-1340.
56. Seliger B., Papadileris S., Vogel D., Hess G., Brendel C., Storkel S., Ortel J., Kolbe K., Huber C., Huhn D., Neubauer A. Analysis of the p53 and mdm2 gene in acute myeloid leukemia. Eur. J. Hematol. 57:1996;230-240.
57. Sigalas I., Calvert A.H., Anderson J.J., Neal D.E., Lunec J. Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences. transforming ability and frequent deletion in human cancer Nat. Med. 2:1996;912-917.
58. Skorski T., Nieborowska-Skorska M., Wlodarski P., Zon G., Iozzo R.V., Calabretta B. Antisense oligodeoxynucleotide combination therapy of primary chronic myelogenous leukemia blast crisis in SCID mice. Blood. 88:1996;1005-1012. a.
59. bcr/abl tyrosine kinase. Proc. Natl. Acad. Sci. USA. 93:1996;13137-13142. b.
60. bcr/abl. implication for RAS-dependent Philadelphia chromosome-positive cell growth J. Exp. Med. 179:1994;1855-1865.
61. Steitz J.A. Immunoprecipitation of ribonucleoproteins using autoantibodies. Dahlberg J.E., Abelson J.N. Methods Enzymol. 180. 1989;Academic Press, Inc, San Diego. 468-481.pp.
62. Tao W., Levine A.J. Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53. Proc. Natl. Acad. Sci. USA. 96:1999;3077-3080.
63. Thut C.J., Goodrich J.A., Tjian R. Repression of p53-mediated transcription by MDM2. a dual mechanism Genes Dev. 11:1997;1974-1986.
64. Topfer F., Gordon T., McCluskey J. Characterization of the mouse auto-antigen La (SS-B). J. Immunol. 150:1993;3091-3100.
65. Wadgaonkar R., Collins T. Murine double minute (MDM2) blocks p53-coactivator interaction, a new mechanism for inhibition of p53-dependent gene expression. J. Biol. Chem. 274:1999;13760-13767.
66. Wetzler M., Talpaz M., Van Etten R.A., Hirsh-Ginsberg C., Beran M., Kurzrock R. Subcellular localization of Bcr-Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation. J. Clin. Invest. 92:1993;1925-1939.
67. Wolin S.L., Cedervall T. The La Protein. Annu. Rev. Biochem. 71:2002;375-403.
68. Zhou M., Yager A.M., Smith S.D., Findley H.W. Overexpression of the MDM2 gene by childhood acute lymphoblastic leukemia cells expressing the wild-type p53 gene. Blood. 85:1995;1608-1614.
69. Zhou M., Gu L., Abshire T.C., Homans A., Billett A.L., Yeager A.M., Findley H.W. Incidence and prognostic significance of MDM2 oncoprotein overexpression in relapsed childhood acute lymphoblastic leukemia. Leukemia. 14:2000;61-67.